• 1
    Kattan MW,Eastham JA,Stapleton AM,Wheeler TM,Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 76671.
  • 2
    Partin AW,Kattan MW,Subong EN,Walsh PC,Wojno KJ,Oesterling JE,Scardino PT,Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 144551.
  • 3
    Stamey TA,Johnstone IM,McNeal JE,Lu AY,Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002; 167: 10311.
  • 4
    Rittenhouse HG,Finlay JA,Mikolajczyk SD,Partin AW. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998; 35: 275368.
  • 5
    Steuber T,Vickers AJ,Haese A,Becker C,Pettersson K,Chun FK,Kattan MW,Eastham JA,Scardino PT,Huland H,Lilja H. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 2006; 118: 123440.
  • 6
    Steuber T,Niemela P,Haese A,Pettersson K,Erbersdobler A,Felix Chun KH,Graefen M,Kattan MW,Huland H,Lilja H. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 2005; 63: 138.
  • 7
    Steuber T,Vickers AJ,Serio AM,Vaisanen V,Haese A,Pettersson K,Eastham JA,Scardino PT,Huland H,Lilja H. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 2007; 53: 23340.
  • 8
    Greene FL,Page DL,Fleming ID,Fritz A,Balch CM,Haller DG,Morrow M. AJCC Cancer Staging Manual, 5th edn., Philadelphia, PA: Lippincott Raven Publishers, 1997.
  • 9
    Sobin LH,Fleming ID. TNM classification of malignant tumors, 5th edn., Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80: 18034.
  • 10
    McNeal JE,Redwine EA,Freiha FS,Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897906.
  • 11
    Amling CL,Bergstralh EJ,Blute ML,Slezak JM,Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 114651.
  • 12
    Mitrunen K,Pettersson K,Piironen T,Bjork T,Lilja H,Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995; 41: 111520.
  • 13
    Vaisanen V,Eriksson S,Ivaska KK,Lilja H,Nurmi M,Pettersson K. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem 2004; 50: 160717.
  • 14
    Vaisanen V,Peltola MT,Lilja H,Nurmi M,Pettersson K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments. Anal Chem 2006; 78: 780915.
  • 15
    Vaisanen V,Pettersson K,Alanen K,Viitanen T,Nurmi M. Free and total human glandular kallikrein 2 in patients with prostate cancer. Urology 2006; 68: 21925.
  • 16
    Pepe M. The statistical evaluation of medical tests for classification and prediction. Oxford Statistical Science Series: Oxford University Press, 2003. 25.
  • 17
    Lilja H,Ulmert D,Bjork T,Becker C,Serio AM,Nilsson JA,Abrahamsson PA,Vickers AJ,Berglund G. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007; 25: 4316.
  • 18
    Lilja H. Biology of prostate-specific antigen. Urology 2003; 62: 2733.
  • 19
    Savblom C,Malm J,Giwercman A,Nilsson JA,Berglund G,Lilja H. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 2005; 65: 6672.
  • 20
    Aus G,Becker C,Lilja H,Khatami A,Pihl CG,Hugosson J. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3). Scand J Urol Nephrol 2003; 37: 46670.
  • 21
    Becker C,Piironen T,Kiviniemi J,Lilja H,Pettersson K. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 2000; 46: 198206.
  • 22
    Darson MF,Pacelli A,Roche P,Rittenhouse HG,Wolfert RL,Saeid MS,Young CY,Klee GG,Tindall DJ,Bostwick DG. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999; 53: 93944.
  • 23
    Haese A,Graefen M,Becker C,Noldus J,Katz J,Cagiannos I,Kattan M,Scardino PT,Huland E,Huland H,Lilja H. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 2003; 54: 1816.
  • 24
    Haese A,Graefen M,Steuber T,Becker C,Pettersson K,Piironen T,Noldus J,Huland H,Lilja H. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001; 49: 1019.
  • 25
    Piironen T,Pettersson K,Suonpaa M,Stenman UH,Oesterling JE,Lovgren T,Lilja H. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996; 48: 817.
  • 26
    Ulmert D,Becker C,Nilsson JA,Piironen T,Bjork T,Hugosson J,Berglund G,Lilja H. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at −20 degrees C. Clin Chem 2006; 52: 2359.